Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Quality of Life After Primary TORS vs IMRT for Patients With Early-stage Oropharyngeal Squamous Cell Carcinoma

Not Applicable

Recruiting

Conditions: Oropharynx Squamous Cell Carcinoma
Carcinoma, Squamous Cell
Carcinoma
Oropharyngeal Neoplasms
Neoplasms, Squamous Cell
Neoplasms by Site
Virus Diseases
DNA Virus Infections
Oropharynx Cancer
Otorhinolaryngologic Neoplasms

Interventions: Procedure: Transoral Robotic Surgery (TORS) with neck dissection
Radiation: Intensity-Modulated Radiation Therapy (IMRT)
Drug: Cisplatin
Drug: Nimorazole.

First Posted Date: 2019-10-11

Last Posted Date: 2022-09-01

Lead Sponsor: Christian von Buchwald

Target Recruit Count: 138

Registration Number: NCT04124198

Locations: 🇩🇰
Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
🇩🇰
Odense University Hospital, Odense, Denmark
🇩🇰
Aarhus University Hospital, Aarhus, Denmark

CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer

Phase 2

Conditions: Cervical Cancer

Interventions: Radiation: Radiotherapy
Drug: Endostar
Drug: Cisplatin

First Posted Date: 2019-10-10

Last Posted Date: 2019-10-10

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 82

Registration Number: NCT04121975

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

Phase 3

Active, not recruiting

Conditions: Oropharyngeal Cancer

Interventions: Drug: Cisplatin
Procedure: Radiotherapy
Drug: Durvalumab

First Posted Date: 2019-10-04

Last Posted Date: 2024-07-29

Lead Sponsor: University of Birmingham

Target Recruit Count: 785

Registration Number: NCT04116047

Locations: 🇬🇧
Colchester General Hospital, Colchester, Essex, United Kingdom
🇬🇧
James Cook University Hospital, Middlesbrough, North Yorkshire, United Kingdom
🇬🇧
Aberdeen Royal Infirmary, Aberdeen, United Kingdom

and more 35 locations

Testing of the Addition of a New Anti-cancer Drug, Molibresib, to Chemotherapy Treatment (Etoposide and Cisplatin) for Patients With NUT Carcinoma

Phase 1

Withdrawn

Conditions: Unresectable NUT Carcinoma
Metastatic NUT Carcinoma

Interventions: Drug: Cisplatin
Drug: Etoposide
Drug: Etoposide Phosphate
Drug: Molibresib
Drug: Molibresib Besylate

First Posted Date: 2019-10-04

Last Posted Date: 2020-09-28

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04116359

Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Phase 2

Terminated

Conditions: Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
KRAS Protein Variant
Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Pathologic Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8

Interventions: Biological: Cetuximab
Drug: Cisplatin
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Radiation: Radiation Therapy

First Posted Date: 2019-09-27

Last Posted Date: 2023-06-01

Lead Sponsor: Jonsson Comprehensive Cancer Center

Target Recruit Count: 1

Registration Number: NCT04106362

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

Phase 2

Recruiting

Conditions: Gastric Cancer
Peritoneal Carcinomatosis

Interventions: Drug: Cisplatin
Drug: Mitomycin

First Posted Date: 2019-09-27

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 21

Registration Number: NCT04107077

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Recurrent Lung Non-Small Cell Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8
Unresectable Lung Non-Small Cell Carcinoma

Interventions: Drug: Carboplatin
Drug: Cisplatin
Biological: Durvalumab
Drug: Etoposide
Drug: Paclitaxel
Drug: Pemetrexed Disodium

First Posted Date: 2019-09-17

Last Posted Date: 2025-01-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 660

Registration Number: NCT04092283

Locations: 🇺🇸
Centralia Oncology Clinic, Centralia, Illinois, United States
🇺🇸
Saint Mary's Hospital, Centralia, Illinois, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 833 locations

Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma

Phase 1

Terminated

Conditions: Unresectable Cholangiocarcinoma
Advanced Cholangiocarcinoma
Metastatic Cholangiocarcinoma

Interventions: Drug: Cisplatin
Drug: Gemcitabine
Drug: Ivosidenib
Drug: Pemigatinib

First Posted Date: 2019-09-12

Last Posted Date: 2024-05-06

Lead Sponsor: Academic and Community Cancer Research United

Target Recruit Count: 8

Registration Number: NCT04088188

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 4 locations

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1

Recruiting

Conditions: Malignant Solid Tumor
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
Pancreatic Ductal Adenocarcinoma (PDAC)

Interventions: Biological: GEN1042
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: 5-FU
Drug: Gemcitabine
Drug: Nab paclitaxel
Drug: Pemetrexed
Drug: Paclitaxel

First Posted Date: 2019-09-10

Last Posted Date: 2025-01-07

Lead Sponsor: Genmab

Target Recruit Count: 1287

Registration Number: NCT04083599

Locations: 🇺🇸
Alaska Oncology and Hematology LLC, Anchorage, Alaska, United States
🇺🇸
Cancer & Blood Specialty Clinic, Los Alamitos, California, United States
🇺🇸
Moores Cancer Center at the UC San Diego Health, San Diego, California, United States

and more 72 locations

Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

Phase 2

Terminated

Conditions: Cholangiocarcinoma
Gallbladder Cancer
Biliary Tract Cancer

Interventions: Drug: M7824
Drug: Placebo
Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2019-08-26

Last Posted Date: 2023-11-14

Lead Sponsor: EMD Serono Research & Development Institute, Inc.

Target Recruit Count: 309

Registration Number: NCT04066491

Locations: 🇺🇸
Methodist Transplant Physicians, Dallas, Texas, United States
🇺🇸
MD Anderson Cancer Center - Unit 429, Houston, Texas, United States
🇺🇸
Renovatio Clinical - CENTRAL SITE, The Woodlands, Texas, United States

and more 96 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy